{"rows":[{"id":5982,"title":"From regulation to practice: A scoping review of prescribers’ roles in psilocybin-assisted therapy","authors":"Bélanger Gabriel, Chang Sue-Ling, Masse-Grenier Marianne, Tremblay Marie-Joëlle, Farzin Houman, Garel Nicolas, Dorval Michel","journal":"Drug Science, Policy and Law","publication_date":"2026-10-01","publication_year":2026,"doi":"10.1177/20503245261494890","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.1177/20503245261494890","substance_tags":"psilocybin","topic_tags":"Mechanism of Action,Review Article,Safety","study_type":"Review Article","source_name":"Crossref","publication_status":"published","date_added":"2026-10-08 01:20:19","last_checked":"2026-10-08 01:20:19","bibtex":null,"source_record_id":"DOI:10.1177/20503245261494890","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.1177/20503245261494890","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"DOI:10.1177/20503245261494890","source_url":"https://doi.org/10.1177/20503245261494890","doi":"10.1177/20503245261494890","pmid":"","publication_date":"2026-10-01","importer_version":"2.1.3","text_redistributed":false}},{"id":5981,"title":"Psilocybin-Assisted Therapy in Depressive Disorders: Clinical Governance, Safety, and Translational Challenges","authors":"Szilvia Salima Bartha Msc In Business Administration","journal":null,"publication_date":"2026-10-05","publication_year":2026,"doi":"10.13140/rg.2.2.17829.05608","pubmed_id":null,"openalex_id":"https://openalex.org/W7220414206","source_url":"https://doi.org/10.13140/rg.2.2.17829.05608","substance_tags":"psilocybin","topic_tags":"Depression,Clinical Trial,Safety","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-10-07 01:20:24","last_checked":"2026-10-08 01:20:23","bibtex":null,"source_record_id":"DOI:10.13140/rg.2.2.17829.05608","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.13140/rg.2.2.17829.05608","source_url":"https://doi.org/10.13140/rg.2.2.17829.05608","doi":"10.13140/rg.2.2.17829.05608","pmid":"","publication_date":"2026-10-05","importer_version":"2.1.3","text_redistributed":false}},{"id":5980,"title":"Caution before canonisation: a clinical and implementation science perspective on psychedelics","authors":"Andreas Paris, Foteïni Thoma, Aikaterini Velentza, Panagiota Pavlopoulou, Giorgos Metaxas","journal":"Frontiers in Psychiatry","publication_date":"2026-10-05","publication_year":2026,"doi":"10.3389/fpsyt.2026.1922928","pubmed_id":null,"openalex_id":"https://openalex.org/W7220367324","source_url":"https://doi.org/10.3389/fpsyt.2026.1922928","substance_tags":"psilocybin","topic_tags":"Depression,PTSD,Addiction,Spirituality,Clinical Trial,Safety","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-10-07 01:20:24","last_checked":"2026-10-08 01:20:23","bibtex":null,"source_record_id":"DOI:10.3389/fpsyt.2026.1922928","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.3389/fpsyt.2026.1922928","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.3389/fpsyt.2026.1922928","source_url":"https://doi.org/10.3389/fpsyt.2026.1922928","doi":"10.3389/fpsyt.2026.1922928","pmid":"","publication_date":"2026-10-05","importer_version":"2.1.3","text_redistributed":false}},{"id":5976,"title":"An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder.","authors":"Tiwari, P.; Nayak, S. M.; Sepeda, N. D.; Ehrenkranz, R.; Levine, M. A.; Rohde, J. S.; Miller, E.; Beritela, C. M.; Scott, J. V.; Nestadt, G.; Barrett, F. S.; Yaden, D. B.","journal":"medRxiv","publication_date":"2026-10-05","publication_year":2026,"doi":"10.64898/2026.10.01.26364511","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.64898/2026.10.01.26364511","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,OCD,Consciousness,Mystical Experience,Clinical Trial,Healthcare Workers,Safety","study_type":"Clinical Trial","source_name":"medRxiv","publication_status":"preprint","date_added":"2026-10-06 01:20:24","last_checked":"2026-10-08 01:20:45","bibtex":null,"source_record_id":"DOI:10.64898/2026.10.01.26364511","abstract_available":true,"abstract_source":"medRxiv","abstract_source_url":"https://doi.org/10.64898/2026.10.01.26364511","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"medRxiv","source_record_id":"DOI:10.64898/2026.10.01.26364511","source_url":"https://doi.org/10.64898/2026.10.01.26364511","doi":"10.64898/2026.10.01.26364511","pmid":"","publication_date":"2026-10-05","importer_version":"2.1.3","text_redistributed":false}},{"id":5974,"title":"Psychedelics and disorders of consciousness: a new frontier in neurotherapeutics.","authors":"Du X, Peng F, Wang X.","journal":"Molecular psychiatry","publication_date":"2026-10-03","publication_year":2026,"doi":"10.1038/s41380-026-03918-4","pubmed_id":"42829371","openalex_id":null,"source_url":"https://doi.org/10.1038/s41380-026-03918-4","substance_tags":"psilocybin","topic_tags":"Neuroplasticity,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Consciousness,Aging,Review Article,Safety","study_type":"Review Article","source_name":"Europe PMC","publication_status":"published","date_added":"2026-10-05 01:20:04","last_checked":"2026-10-08 01:20:20","bibtex":null,"source_record_id":"PMID:42829371","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1038/s41380-026-03918-4","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42829371","source_url":"https://doi.org/10.1038/s41380-026-03918-4","doi":"10.1038/s41380-026-03918-4","pmid":"42829371","publication_date":"2026-10-03","importer_version":"2.1.3","text_redistributed":false}},{"id":5973,"title":"Serotonergic Toxicity and Hyponatremia Associated with Antidepressant Therapy: The Pivotal Role of SIADH.","authors":"Morena D, Lippi M, Biso L, Lucci F, Turillazzi E, Fineschi V, Scognamiglio P.","journal":"Clinical drug investigation","publication_date":"2026-10-03","publication_year":2026,"doi":"10.1007/s40261-026-01599-z","pubmed_id":"42829418","openalex_id":"https://openalex.org/W7218417106","source_url":"https://doi.org/10.1007/s40261-026-01599-z","substance_tags":"psilocybin","topic_tags":"Addiction,Pharmacology,Mechanism of Action,Receptor Pharmacology,Review Article,Case Report,Safety,Toxicity,Drug Interactions","study_type":"Review Article","source_name":"Europe PMC","publication_status":"published","date_added":"2026-10-05 01:20:04","last_checked":"2026-10-08 01:20:23","bibtex":null,"source_record_id":"PMID:42829418","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1007/s40261-026-01599-z","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42829418","source_url":"https://doi.org/10.1007/s40261-026-01599-z","doi":"10.1007/s40261-026-01599-z","pmid":"42829418","publication_date":"2026-10-03","importer_version":"2.1.3","text_redistributed":false}},{"id":5959,"title":"Psilocybin for Treatment-Resistant Major Depression: Efficacy, Safety and Therapeutic Mechanisms","authors":"Lea Julia Mertens","journal":null,"publication_date":"2026-09-24","publication_year":2026,"doi":"10.11588/heidok.00039377","pubmed_id":null,"openalex_id":"https://openalex.org/W7214153504","source_url":"https://doi.org/10.11588/heidok.00039377","substance_tags":"psilocybin","topic_tags":"Depression,Pharmacology,Mechanism of Action,Treatment-Resistant Depression,Safety","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-09-26 01:20:21","last_checked":"2026-10-01 01:20:28","bibtex":null,"source_record_id":"DOI:10.11588/heidok.00039377","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.11588/heidok.00039377","source_url":"https://doi.org/10.11588/heidok.00039377","doi":"10.11588/heidok.00039377","pmid":"","publication_date":"2026-09-24","importer_version":"2.1.3","text_redistributed":false}},{"id":5958,"title":"Age moderates the relationship between psychedelic use and mental health in naturalistic settings","authors":"Giammarco Di Gregorio, Basset Sophia, Harjot Manmohan, Warren C. Nixon, Amrutha Pogaku, Jing Zhou, David J. Sanderson, Michael L. Lengieza, Marco Bocchio","journal":"Scientific Reports","publication_date":"2026-09-24","publication_year":2026,"doi":"10.1038/s41598-026-68283-2","pubmed_id":null,"openalex_id":"https://openalex.org/W7204099123","source_url":"https://doi.org/10.1038/s41598-026-68283-2","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Chronic Pain,Aging,Longevity,Mystical Experience,Clinical Trial,Observational Study,Older Adults,Safety,Toxicity","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-09-26 01:20:21","last_checked":"2026-10-01 01:20:28","bibtex":null,"source_record_id":"DOI:10.1038/s41598-026-68283-2","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1038/s41598-026-68283-2","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1038/s41598-026-68283-2","source_url":"https://doi.org/10.1038/s41598-026-68283-2","doi":"10.1038/s41598-026-68283-2","pmid":"","publication_date":"2026-09-24","importer_version":"2.1.3","text_redistributed":false}},{"id":5955,"title":"Apomorphine and psilocybin to improve recovery from coma in the intensive care unit: protocol for a prospective, open-label, dose-escalation study.","authors":"Eigenbrodt AK, Laigaard PP, Hassani M, Othman MH, Amiri M, Møller K, Kjaergaard J, Kondziella D","journal":"BMJ open","publication_date":"2026-09-22","publication_year":2026,"doi":"10.1136/bmjopen-2026-124508","pubmed_id":"42772877","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/42772877/","substance_tags":"psilocybin","topic_tags":"Consciousness,Clinical Trial,Review Article,Observational Study,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-09-24 01:20:06","last_checked":"2026-09-29 01:20:04","bibtex":null,"source_record_id":"PMID:42772877","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/42772877/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:42772877","source_url":"https://pubmed.ncbi.nlm.nih.gov/42772877/","doi":"10.1136/bmjopen-2026-124508","pmid":"42772877","publication_date":"2026-09-22","importer_version":"2.1.3","text_redistributed":false}},{"id":5953,"title":"ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted Therapy","authors":"University of Minnesota","journal":"ClinicalTrials.gov","publication_date":"2026-09-22","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07833761","substance_tags":"psilocybin","topic_tags":"Depression,Personality Change,Emotional Processing,Mystical Experience,Safety,Adverse Events","study_type":"Other","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-09-23 01:38:32","last_checked":"2026-09-29 01:24:26","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT07833761","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT07833761","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT07833761","source_url":"https://clinicaltrials.gov/study/NCT07833761","doi":"","pmid":"","publication_date":"2026-09-22","importer_version":"2.1.3","text_redistributed":false}},{"id":5950,"title":"Exploring the Therapeutic Potential of Psilocybin: A Comprehensive Review of Clinical Trial Evidence and Implications for Rescheduling.","authors":"Abolhasani F, Rezaiezadeh H, Langarizadeh MA, Tavakoli MR, Ilaghi M, Zare P, Ravari FK, Alamdar F, Banazadeh M, Shabani M.","journal":"Mini reviews in medicinal chemistry","publication_date":"2026-09-18","publication_year":2026,"doi":"10.2174/0113895575443239260828094859","pubmed_id":"42770437","openalex_id":"https://openalex.org/W7213987315","source_url":"https://doi.org/10.2174/0113895575443239260828094859","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,PTSD,Addiction,Headache / Migraine,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Wellbeing,Emotional Processing,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-23 01:20:07","last_checked":"2026-09-25 01:20:21","bibtex":null,"source_record_id":"PMID:42770437","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.2174/0113895575443239260828094859","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42770437","source_url":"https://doi.org/10.2174/0113895575443239260828094859","doi":"10.2174/0113895575443239260828094859","pmid":"42770437","publication_date":"2026-09-18","importer_version":"2.1.3","text_redistributed":false}},{"id":5948,"title":"EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW","authors":"Gawin Mateusz, Koziara Emilia, Gadzina Mateusz, Gawlak Julia, Krzesimir Kuświk Maciej, Tarnawska Zofia, Figiel Karolina, Sontag Wojciech, Zawisza Mateusz, Golec Aleksandra","journal":"International Journal of Innovative Technologies in Social Science","publication_date":"2026-09-21","publication_year":2026,"doi":"10.31435/ijitss.3(51).2026.6573","pubmed_id":null,"openalex_id":"https://openalex.org/W7213945218","source_url":"https://doi.org/10.31435/ijitss.3(51).2026.6573","substance_tags":"psilocybin,psilocin","topic_tags":"Depression,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"Crossref","publication_status":"published","date_added":"2026-09-22 01:20:19","last_checked":"2026-09-28 01:20:29","bibtex":null,"source_record_id":"DOI:10.31435/ijitss.3(51).2026.6573","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.31435/ijitss.3(51).2026.6573","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"DOI:10.31435/ijitss.3(51).2026.6573","source_url":"https://doi.org/10.31435/ijitss.3(51).2026.6573","doi":"10.31435/ijitss.3(51).2026.6573","pmid":"","publication_date":"2026-09-21","importer_version":"2.1.3","text_redistributed":false}},{"id":5947,"title":"A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults","authors":"Levy-Cooperman Naama, Sellers Edward, Glue Paul, Szeto Isabella, Brown David, Jarecki-Smith Jamie, Tyler William J., McDonnell Michael B.","journal":"Pharmaceuticals","publication_date":"2026-09-21","publication_year":2026,"doi":"10.3390/ph19091496","pubmed_id":"42797541","openalex_id":"https://openalex.org/W7213877811","source_url":"https://doi.org/10.3390/ph19091496","substance_tags":"psilocybin,psilocin","topic_tags":"Pharmacology,Clinical Trial,Review Article,Observational Study,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"Crossref","publication_status":"published","date_added":"2026-09-22 01:20:19","last_checked":"2026-09-28 01:20:29","bibtex":null,"source_record_id":"PMID:42797541","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.3390/ph19091496","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"PMID:42797541","source_url":"https://doi.org/10.3390/ph19091496","doi":"10.3390/ph19091496","pmid":"42797541","publication_date":"2026-09-21","importer_version":"2.1.3","text_redistributed":false}},{"id":5946,"title":"Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants.","authors":"Signor A, Comai S, Pasut G, Folli F, Gentilucci M, Gharavi N, Raitsin S, Van Nguyen T, Pappagallo M, Mattarei A, Manfredi PL, De Martin S.","journal":"British journal of clinical pharmacology","publication_date":"2026-09-21","publication_year":2026,"doi":"10.1002/bcp.70839","pubmed_id":"42767271","openalex_id":"https://openalex.org/W7213916889","source_url":"https://doi.org/10.1002/bcp.70839","substance_tags":"psilocybin,psilocin","topic_tags":"Pharmacology,Clinical Trial,Animal Study,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-22 01:20:18","last_checked":"2026-09-28 01:20:29","bibtex":null,"source_record_id":"PMID:42767271","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1002/bcp.70839","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42767271","source_url":"https://doi.org/10.1002/bcp.70839","doi":"10.1002/bcp.70839","pmid":"42767271","publication_date":"2026-09-21","importer_version":"2.1.3","text_redistributed":false}},{"id":5945,"title":"Targeting the serotonin 1B receptor for the treatment of depression and anxiety.","authors":"Fleury S, Nautiyal KM.","journal":"Expert opinion on therapeutic targets","publication_date":"2026-09-28","publication_year":2026,"doi":"10.1080/14728222.2026.2738183","pubmed_id":"42766349","openalex_id":"https://openalex.org/W7213928055","source_url":"https://doi.org/10.1080/14728222.2026.2738183","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,End-of-Life Distress,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Biomarkers,Clinical Trial,Animal Study,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-22 01:20:05","last_checked":"2026-10-05 01:20:16","bibtex":null,"source_record_id":"PMID:42766349","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1080/14728222.2026.2738183","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42766349","source_url":"https://doi.org/10.1080/14728222.2026.2738183","doi":"10.1080/14728222.2026.2738183","pmid":"42766349","publication_date":"2026-09-28","importer_version":"2.1.3","text_redistributed":false}},{"id":5944,"title":"Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward.","authors":"Mallevays M, Berkovitch L.","journal":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology","publication_date":"2026-09-19","publication_year":2026,"doi":"10.1016/j.euroneuro.2026.113878","pubmed_id":"42762543","openalex_id":"https://openalex.org/W7213658706","source_url":"https://doi.org/10.1016/j.euroneuro.2026.113878","substance_tags":"psilocybin","topic_tags":"Mechanism of Action,Safety","study_type":"Other","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-21 01:20:06","last_checked":"2026-09-26 01:20:21","bibtex":null,"source_record_id":"PMID:42762543","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1016/j.euroneuro.2026.113878","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42762543","source_url":"https://doi.org/10.1016/j.euroneuro.2026.113878","doi":"10.1016/j.euroneuro.2026.113878","pmid":"42762543","publication_date":"2026-09-19","importer_version":"2.1.3","text_redistributed":false}},{"id":5943,"title":"Perceptions and Attitudes on Psilocybin-Assisted Therapy among Underrepresented People with Cancer.","authors":"Miller M, Meyers M, Oglesby-Adepoju C, Elk R, Beaussaunt Y.","journal":"Journal of pain and symptom management","publication_date":"2026-09-18","publication_year":2026,"doi":"10.1016/j.jpainsymman.2026.09.018","pubmed_id":"42759904","openalex_id":null,"source_url":"https://doi.org/10.1016/j.jpainsymman.2026.09.018","substance_tags":"psilocybin","topic_tags":"End-of-Life Distress,Cancer Patients,Safety","study_type":"Qualitative Study","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-20 01:20:05","last_checked":"2026-09-25 01:20:16","bibtex":null,"source_record_id":"PMID:42759904","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1016/j.jpainsymman.2026.09.018","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42759904","source_url":"https://doi.org/10.1016/j.jpainsymman.2026.09.018","doi":"10.1016/j.jpainsymman.2026.09.018","pmid":"42759904","publication_date":"2026-09-18","importer_version":"2.1.3","text_redistributed":false}},{"id":5942,"title":"An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.","authors":"Downey AE, Szigeti B, Bradley ER, Fernandes-Osterhold G, Sakai K, Llerena K, Fredenburg L, Nerayo J, Evans-Riera L, Nielsen B, Krystal AD, O'Donovan A, Gard DE, Woolley JD.","journal":"The Journal of clinical psychiatry","publication_date":"2026-09-21","publication_year":2026,"doi":"10.4088/jcp.25m16227","pubmed_id":"42765891","openalex_id":"https://openalex.org/W7213540649","source_url":"https://doi.org/10.4088/jcp.25m16227","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Headache / Migraine,Safety,Adverse Events","study_type":"Other","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-19 01:20:18","last_checked":"2026-09-28 01:20:25","bibtex":null,"source_record_id":"PMID:42765891","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.4088/jcp.25m16227","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42765891","source_url":"https://doi.org/10.4088/jcp.25m16227","doi":"10.4088/jcp.25m16227","pmid":"42765891","publication_date":"2026-09-21","importer_version":"2.1.3","text_redistributed":false}},{"id":5940,"title":"Comparative Policy Analysis of Psychedelic Therapy Regulation in Australia, Brazil, and the USA","authors":"A S Shikha, Jignesh Shah, Darshil B. Shah, Dilip Maheshwari","journal":"Applied Drug Research Clinical Trials and Regulatory Affairs","publication_date":"2026-09-14","publication_year":2026,"doi":"10.2174/0126673371488041260902064242","pubmed_id":null,"openalex_id":"https://openalex.org/W7213466340","source_url":"https://doi.org/10.2174/0126673371488041260902064242","substance_tags":"psilocybin","topic_tags":"Mechanism of Action,Review Article,Safety,Toxicity","study_type":"Review Article","source_name":"OpenAlex","publication_status":"published","date_added":"2026-09-18 01:20:21","last_checked":"2026-09-21 01:20:28","bibtex":null,"source_record_id":"DOI:10.2174/0126673371488041260902064242","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.2174/0126673371488041260902064242","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.2174/0126673371488041260902064242","source_url":"https://doi.org/10.2174/0126673371488041260902064242","doi":"10.2174/0126673371488041260902064242","pmid":"","publication_date":"2026-09-14","importer_version":"2.1.3","text_redistributed":false}},{"id":5939,"title":"High ventilation breathwork as a non-pharmacological model for inducing psychedelic-like states: expert evaluations of therapeutic potential and risk.","authors":"Lueken U, Dziobek I, Havenith MN, Schild M, Daedelow LS.","journal":"Npj mental health research","publication_date":"2026-09-17","publication_year":2026,"doi":"10.1038/s44184-026-00246-x","pubmed_id":"42754646","openalex_id":"https://openalex.org/W7213457361","source_url":"https://doi.org/10.1038/s44184-026-00246-x","substance_tags":"psilocybin","topic_tags":"Mechanism of Action,Consciousness,Emotional Processing,Clinical Trial,Safety,Contraindications","study_type":"Clinical Trial","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-18 01:20:21","last_checked":"2026-09-24 01:20:20","bibtex":null,"source_record_id":"PMID:42754646","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1038/s44184-026-00246-x","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42754646","source_url":"https://doi.org/10.1038/s44184-026-00246-x","doi":"10.1038/s44184-026-00246-x","pmid":"42754646","publication_date":"2026-09-17","importer_version":"2.1.3","text_redistributed":false}}],"total":1251,"page":1,"per_page":20,"pages":63,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":"Safety","study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":null,"from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}